Information  X 
Enter a valid email address

Byotrol PLC (BYOT)

  Print          Annual reports

Tuesday 02 November, 2021

Byotrol PLC

Directorate and Senior Management Changes

RNS Number : 9864Q
Byotrol PLC
02 November 2021
 

 

 

Byotrol plc ("Byotrol" or the "Company")

Directorate and Senior Management Changes

 

The Board of Byotrol announces changes to the Board of Directors and senior management positions within the Company.

Nic Hellyer, our part-time CFO since May 2019, has stated his intention to resign from the Company to pursue other interests.  Byotrol is now in advanced discussions to replace him with a full-time CFO to be based in our Chester headquarters.  Nic has agreed to stay on to manage the transition until the end of December.

Rick Hayman, head of Byotrol's Professional division and Managing Director of Medimark Scientific Limited, which Byotrol formally acquired in January 2020, has now left Byotrol, but remains a supportive shareholder with a continued interest in the Company's future.  Rick has been replaced by Mark Kyte, formerly a senior sales and marketing professional at Diversey and at Gojo Industries, two of the leading companies worldwide in our core areas of business.

 

We are also pleased to announce the hiring of James Milnes as a senior business development professional.  James was previously UK MD of Zoono Holdings Ltd and in that role launched and led the team responsible for building Zoono's long-lasting antimicrobial business in the UK and Europe. 

Finally, we have restructured our technical team in readiness for the next stage of growth and have now promoted Dr Chris Plummer, previously head of microbiology at Byotrol, to Head of Technology.

 

David Traynor, Chief Executive of Byotrol, said:

 

We thank Nic and Rick for their contributions to Byotrol and we wish them every success in the future.

The Byotrol board has been very pleased with Dr Chris Plummer's excellent work to date in our technical team and his promotion to Head of Technology is very well deserved.  We are also delighted to welcome Mark Kyte and James Milnes into the business and look forward to their contribution to our growth. We are very pleased to be attracting such seasoned professionals into Byotrol as we look to build a significantly larger business.

 

Enquiries:

 

Enquiries:

 

Byotrol plc 

David Traynor - Chief Executive Officer

Nic Hellyer - Chief Financial Officer    01925 742 000

 

finnCap

Geoff Nash/Kate Bannatyne - Corporate Finance    020 7220 0500

Richard Chambers - ECM

 

Flagstaff Strategic and Investor Communications

Tim Thompson/Andrea Seymour/Fergus Mellon   020 7129 1474

[email protected]

 

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

 

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to byotrol.co.uk

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADKDBDFBDDADK

a d v e r t i s e m e n t